Background Irreversible inhibition of Bruton’s tyrosine kinase (BTK) by ibrutinib represents
an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). …

Background Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and …

Background Ibrutinib has been approved by the Food and Drug Administration for the
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not …

Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity
in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without …

Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton’s tyrosine kinase (BTK) …

Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell
malignancies, but patients discontinue these agents due to resistance and intolerance. …

Given its critical role in T-cell signaling, interleukin-2–inducible kinase (ITK) is an appealing
therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, …

Importance The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and …

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United
States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small …

Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed
the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic …